In summary, many studies have found that high LGR5 expression is associated with chemoresistance in breast, cervical, colorectal, hepatic, gastric and ovarian cancer to a wide range of chemotherapy drugs including carboplatin, cisplatin, paclitaxel oxaliplatin, 5-FU and doxorubicin. Here, LGR5 is linked to ovarian carcinoma.